Article Content



* Read the article. The test for this CE activity can only be taken online at


* INS members: Before you go to the test, go to for INS member benefit information. You can go to the JIN CE test area from there.


* Tests can no longer be mailed or faxed. You will need to create a user account (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.


* There is only 1 correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours (CHs) and access the answer key. If you fail, you have the option of taking the test again at no additional cost.


* For questions, contact Lippincott Professional Development customer service: 1-800-787-8985.



Registration Deadline: September 2, 2022


Provider Accreditation:


Lippincott Professional Development will award 1.5 CHs including 1.5 pharmacology hours for this continuing nursing education activity.


Lippincott Professional Development is accredited as a provider of CNE by the American Nurses Credentialing Center's Commission on Accreditation.


This activity is also provider-approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 CHs. Lippincott Professional Development is also an approved provider of CNE by the District of Columbia, Georgia, and Florida, CE Broker #50-1223. Your certificate is valid in all states.


Disclosure: The authors and planners have disclosed that they have no financial relationships related to this publication.


Payment and Discounts:


* The registration fees for this test are: For INS members: $11.25; for non-INS members: $12.75.


* INS members can take the test at the reduced rate by logging into the secure "Members Only" area at






GENERAL PURPOSE: To provide information about the 2019 guidelines from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) for the diagnosis and treatment of community-acquired pneumonia (CAP) in adults.


LEARNING OBJECTIVES/OUTCOMES: After completing this continuing education activity, you should be able to:


1. Explain issues related to CAP and recommendations from the IDSA and ATS for the treatment of CAP in adults.


2. Select new therapeutic alternatives for the treatment of a patient with community-acquired bacterial pneumonia.



1. For an outpatient with CAP and no comorbidities or risk factors for methicillin-resistantStaphylococcus aureus(MRSA) orPseudomonas aeruginosa, one of the antibiotic options recommended in the 2019 IDSA/ATS Guidelines for initial treatment is


a. cefadroxil


b. amoxicillin


c. levofloxacin


2. Comorbidities considered in the 2019 Guidelines include all of the following except


a. asplenia.


b. alcoholism.


c. Crohn's disease.


3. For treatment of an inpatient with non-severe pneumonia, the standard regimen includes a beta lactam + macrolide OR


a. vancomycin.


b. piperacillin-tazobactam.


c. respiratory fluoroquinolone.


4. The 2019 Guidelines recommend that an inpatient with non-severe pneumonia who has had prior respiratory isolation ofP aeruginosashould receive the standard regimen plus which of the following as an option?


a. ceftazidime


b. vancomycin


c. amoxicillin


5. For an inpatient with severe pneumonia and prior respiratory isolation of MRSA, an option recommended by the 2019 Guidelines is to add


a. cefepime.


b. linezolid.


c. imipenem.


6. As noted in the article, risk factors for developing drug-resistantStreptococcus pneumoniaein adults include


a. age 25 to 45 years.


b. working or living in a humid, indoor environment.


c. exposure to a child cared for in a daycare center.


7. The unique mechanism of action of lefamulin is hypothesized to lessen the development of


a. allergic reaction.


b. resistance.


c. Clostridium difficile infection.


8. In their 2019 study, File et al concluded that lefamulin for the treatment of patients with pneumonia was noninferior to


a. moxifloxacin.


b. azithromycin.


c. cefuroxime.


9. The most common adverse effects reported with lefamulin include


a. dizziness.


b. headache.


c. insomnia.


10. Lefamulin should be avoided in patients with known


a. left bundle branch block.


b. QT prolongation.


c. atrial fibrillation.


11. The recommended intravenous (IV) dose of lefamulin is a 60-minute infusion of


a. 150 mg every 12 hours.


b. 300 mg every 12 hours.


c. 600 mg every 12 hours.


12. What class of antibiotic is omadacycline?


a. fluoroquinolone


b. macrolide


c. tetracycline


13. One of the most common adverse effects from omadacycline is


a. hypertension.


b. diarrhea.


c. skin rash.


14. What is the recommended IV loading dose of omadacycline to be administered over 60 minutes?


a. 100 mg


b. 150 mg


c. 200 mg


15. Delafloxacin has activity against


a. Coxiella burnetii.


b. Moraxella catarrhalis.


c. Haemophilus influenzae.


16. The most common adverse events reported in patients treated with delafloxacin include elevations in


a. lipase.


b. transaminase.


c. creatine kinase.


17. Like other fluoroquinolones, the labeling of delafloxacin contains warnings about the risks of serious adverse effects such as


a. tendon rupture.


b. pulmonary emboli.


c. osteonecrosis of the jaw.


18. Structural differences in the delafloxacin molecule as compared with the other fluoroquinolones seem to reduce the incidence of


a. agitation.


b. phototoxicity.


c. neuropathy.